Combined criteria for dose optimisation in early phase clinical trials

DOI10.1002/SIM.8292zbMATH Open1545.62198MaRDI QIDQ6625215FDOQ6625215

Authors: M. Iftakhar Alam, D. Stephen Coad, Barbara Bogacka 

Publication date: 28 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

penalty functionadaptive designcontinuation ratio model\(D\)-optimum designphase I/II trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Adaptive designs for dose-finding based on efficacy-toxicity response
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Optimum experimental designs, with SAS
• Title not available (Why is that?)
• Experimental design in a class of models
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response
• Model-oriented design of experiments
• Penalized optimal designs for dose-finding
• Adaptive optimization and \(D\)-optimum experimental design.
• Optimal designs and limiting optimal designs for a trinomial response
• Elemental information matrices and optimal experimental design for generalized regression models
• Optimal Designs for Bivariate Logistic Regression
• Adaptive design in regression and control
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• Directed walk designs for dose-response problems with competing failure modes
• Simple benchmark for complex dose finding studies

This page was built for publication: Combined criteria for dose optimisation in early phase clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6625215)